How to reduce healthcare costs is the organisation playbook: value-based care, pharmacy / biosimilars, administrative automation, and a culture that notices waste. It is not an ops-efficiency explainer and not a readmission programme.
If you meant operational efficiency (how the hospital runs) → operational efficiency in healthcare. If you meant readmissions → reducing hospital readmission rates. If you meant resource allocation (who gets the ICU bed) → healthcare resource allocation. If you meant HIPAA transfer → HIPAA-compliant data transfer.
This page is four strategies, utilisation / GPO / pathways, then a short consumer / employer appendix. PYCAD is not a cost-containment suite.
Four strategies
- Value-based care — pay for outcomes, not volume. Fee-for-service pays for every bolt; VBC pays for a car that runs. Prevention, chronic-disease management, and a coordinated team (PCP + specialists who share a plan) cut the expensive events: ED visits, duplicate tests, preventable stays. Treat “$1T by 2025” slides as unsourced unless you can open the primary source.
- Pharmacy / biosimilars — specialty drugs are a large, movable line. Biosimilars are the generic-equivalent move for biologics: same clinical job, lower price once interchange is allowed and the formulary actually switches. Pair with prior auth, step therapy, and quantity limits that are clinical, not obstruction.
- Admin automation — coding, claims, eligibility, prior auth. The waste is rework on denials and duplicate data entry. Automate the clean claims; keep a human on exceptions. Imaging AI that shortens a read is a cost tool only when TAT and repeat scans actually fall — it is not a second operations product.
- Culture of cost-consciousness — standardised clinical pathways so two similar patients do not get two different (and differently priced) workups; utilisation review on high-variance imaging and labs; a GPO or committed contract so supplies are not bought at panic prices.
Utilisation, GPO, pathways
Utilisation management is “is this service indicated,” not “deny until they call.” Pathways (order sets for a diagnosis) cut unexplained variation. GPOs and committed volume buy price; they do not fix a department that over-orders because the preference card is stale. Track cost per discharge and denial rate, not a vendor’s market forecast.
Public investment, short
What a household pays is partly what the state already absorbed. High-income countries spent about 5.8% of GDP on public healthcare in 2022; low-income countries about 1.2% (HRW on the financing gap). Public spend buys bargaining power on drugs, funds prevention, and stops a bill from becoming a household crisis. It is not a substitute for the four strategies above.
Individuals and employers
For a person: use the covered preventive visit; ask for the generic (often 30–80% cheaper for the same active ingredient); read the itemised bill for duplicate lines. Pick a plan on deductible + out-of-pocket max, not premium alone.
| Employer move | Job | Effort |
|---|---|---|
| Wellness that is actually used | Screening, chronic-disease coaching — not a step-counter contest | Moderate |
| HSA + high-deductible (when it fits) | Pre-tax spend, a reason to price-shop | Low |
| Telehealth as first contact | Low-acuity visits without an ED bill or a half-day off | Low–moderate |
| Price-transparency tools | Let staff compare a cash price before a routine procedure | Moderate |
PYCAD builds custom web DICOM viewers and medical-imaging AI — a connector / imaging stack, not a cost-containment or hospital-ops platform. Case studies.